Opendata, web and dolomites

SIRENE

Silencing miR-199b to attenuate the progression of heart failure.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 SIRENE project word cloud

Explore the words cloud of the SIRENE project. It provides you a very rough idea of what is the project "SIRENE" about.

generation    arrhythmias    endogenous    implicated    erc    marks    business    commercialisation    efficacy    sirene    valuable    therapeutic    class    lethal    recognition    ip    web    symptoms    interconnected    coding    risk    principal    mir    animal    heart    affinity    preclinical    proposition    demonstrates    overload    species    strategy    regulate    counteracting    promise    molecules    consolidate    venture    morphological    rats    shown    capitalists    feasibility    clinical    199b    stage    found    silencing    micrornas    rescue    dose    specificity    knockdown    adult    mouse    leads    market    sustained    mice    strength    mirnas    hypertrophic    calmirs    functional    vivo    longer    model    abnormalities    rna    strategic    protective    mirna    cardiac    data    molecular    powerful    therapeutics    presenting    holds    commercial    hypertrophy    antagonists    models    pathological    pressure    histological    simultaneously    newly    profound    signalling    larger    clinically   

Project "SIRENE" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITEIT MAASTRICHT 

Organization address
address: Minderbroedersberg 4-6
city: MAASTRICHT
postcode: 6200 MD
website: http://www.maastrichtuniversity.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 150˙000 €
 EC max contribution 150˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2014-PoC
 Funding Scheme ERC-POC
 Starting year 2015
 Duration (year-month-day) from 2015-09-01   to  2017-02-28

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITEIT MAASTRICHT NL (MAASTRICHT) coordinator 150˙000.00

Map

 Project objective

Cardiac hypertrophy is the principal risk factor for the development of heart failure and lethal arrhythmias. A complex web of interconnected signalling pathways has been implicated in hypertrophy and species of non-coding RNA molecules, microRNAs, have been shown to regulate these pathways. The recognition of microRNAs as potential therapeutic targets marks the principal step towards new therapeutic concepts. The SIRENE project represents the advancement of the therapeutic strength of miRNA silencing in clinically relevant heart failure models towards a valuable proposition for counteracting pathological hypertrophic signalling and heart failure development. In specific, during the related ERC CALMIRS project, it was found that sustained knockdown of endogenous miR-199b in the adult mouse heart in vivo leads to profound protective effects against symptoms of heart failure. Therefore, a new class of RNA antagonists, targeting miRNAs is powerful and holds great promise to become the next generation therapeutics. At this stage the newly developed antagonists are unique in their affinity and specificity for miR-199b and current data demonstrates a profound rescue by miR-199b antagonists on heart failure symptoms such as pressure overload induced cardiac morphological, histological, functional and molecular abnormalities in mice. The challenge of the SIRENE project is to identify immediate and longer term opportunities for commercialisation with high clinical and commercial feasibility. Therefore different business models will be studied in terms of market research, IP strategy and business development to eventually consolidate a commercial strategy and business case for presenting our business proposition to strategic partners or venture capitalists. Simultaneously, dose-range finding and efficacy studies will be conducted in rats, a clinically relevant and larger animal model of heart failure, for further preclinical development.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SIRENE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SIRENE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

NanoPD_P (2020)

High throughput multiplexed trace-analyte screening for diagnostics applications

Read More  

PROGRESS (2019)

The Enemy of the Good: Towards a Theory of Moral Progress

Read More  

TOROS (2019)

A Theory-Oriented Real-Time Operating System for Temporally Sound Cyber-Physical Systems

Read More